- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Theradiag Partners with Biogaran on Infliximab Biosimilar Monitoring Kits in France
Last week, Theradiag, a French company specializing in in vitro diagnostics and theranostics (targeted therapy based on findings in diagnostic tests) announced that it has entered a new partnership agreement with pharmaceutical group Biogaran.
Last week, Theradiag, a French company specializing in in vitro diagnostics and theranostics (targeted therapy based on findings in diagnostic tests) announced that it has entered a new partnership agreement with pharmaceutical group Biogaran.
Biogaran is a French pharmaceutical group that specializes in generics. In 2014, Biogaran Biosimilars was created, and in February the following year, Celltrion’s biosimilar infliximab (marketed in the European Union as Remsima) was launched in France by Biogaran.
Through this agreement, Biogaran will offer its Lisa Tracker monitoring kits throughout France to support the biosimilar, and Theradiag will handle implementation, provide training to laboratories, and provide clinician support concerning drug monitoring.
The Lisa Tracker kits are used to monitor patients taking anti-tumor necrosis factor (anti-TNF) treatments for various chronic inflammatory diseases. The kit allows clinicians to monitor patient’s trough plasma levels of circulating tumor necrosis factor (TNF), anti-TNF drug levels, and levels of anti-drug antibodies. The combination of these measurements allows physicians to better optimize the patient’s treatment.
In November 2017, Theradiag announced a similar partnership with another pharmaceutical company, Biogen, to provide the Lisa Tracker kits to its patients treated with another infliximab biosimilar, Flixabi, in France and other European nations.
“Together with our partnerships with Janssen, MSD, Pfizer, and Biogen, this deal with Biogaran will enable us to supply our Lisa Tracker kits with all the infliximabs in the market and also for other monoclonal antibodies. It’s also very good news for doctors and their patients, as it will facilitate more personalized therapies,” said Michel Finance, Theradiag’s CEO.
AAM Report: Generics and Biosimilars Savings Reach $445 Billion in 2023, Part 1
September 18th 2024Savings from generic and biosimilar drugs totaled $445 billion in 2023, showing promise for the growth of both markets and highlighting the success of expansion policies for these products, according to a new report from the Association for Accessible Medicines (AAM).
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Expanding Biosimilar Adoption: Insights and Strategies With Dr Sophia Humphreys
September 16th 2024Sophia Humphreys, PharmD, MHA, BCBBS, director of system formulary management at Sutter Health, discusses the challenges of expanding biosimilars into new therapeutic areas and highlights the role of education, competitive pricing, and integrated delivery networks in improving adoption and market growth.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
BioRationality: FDA Clarification Provides New Indications and Process Change for Biosimilars
September 9th 2024Sarfaraz K. Niazi, PhD, explains the FDA's new guidelines on post-approval changes for biosimilars, emphasizing the processes for reporting modifications, comparability assessments, and the potential for biosimilars to introduce new indications or formulation changes, which could significantly impact their market competitiveness and accessibility.
The Role of Coverage Strategies in Biosimilar Market Impact and Cost Savings
September 4th 2024A recent study highlights that although biosimilars have led to significant price reductions, originator products with sole preferred coverage strategies have maintained market share, suggesting that increased biosimilar uptake alone may not fully leverage the market's competitive and cost-saving potential.
